<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CETRORELIX</span><br/>(ce-tro-re'lix)<br/><span class="topboxtradename">Cetrotide<br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">gonadotropin-releasing hormone antagonist</span><br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.25 mg, 3 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Centrotide is a luteinizing hormone-releasing hormone (LHRH) antagonist.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It prevents premature LH surges in patients undergoing controlled ovarian hyperstimulation for assisted reproduction.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of infertility as part of an assisted reproduction program.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cetrorelix, extrinsic peptide hormones, mannitol, gonadotropin-releasing hormone analogs; pregnancy (category
         X); known or suspected pregnancy; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic insufficiency.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Infertility</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 0.25 mg/d during the early to mid follicular phase of the cycle (stimulation day 5 or 6) following the initiation of FSH or
               3 mg as a single dose is administered when the serum estradiol level is indicative of an appropriate stimulation response,
               usually on FSH stimulation day 7 (range day 59). If HCG has not been administered within 4 d after the injection of
               3 mg, then 0.25 mg should be administered once daily until the day of HCG administration<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Reconstitute the 0.25 or 3 mL vial with 1 or 3 mL, respectively, of sterile water for injection.</li>
<li>Inject into lower abdominal wall following reconstitution. Rotate injection sites.</li>
<li>Store the 3 mg dose at room temperature, 15°30° C (59°86° F). Store the 0.25 mg dose in the
            refrigerator.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span> Nausea, vomiting, abdominal pain. <span class="typehead"> Endocrine:</span>  Hot flashes. <span class="typehead">Skin:</span> Pruritus at injection site. <span class="typehead">Urogenital:</span> Ovarian enlargement, ovarian hyperstimulation syndrome, pelvic pain. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cimetidine,</b>
<b>methyldopa,</b>
<b>metoclopramide,</b>
<b>reserpine,</b>
<span class="classification">phenothiazines</span> may interfere with fertility efforts. <span class="typehead">Herbal:</span>
<b>Black cohosh,</b>
<b>DHEA</b> may antagonize fertility efforts. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 85% absorbed from SC injection site. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Metabolism:</span> Metabolized by peptidases. <span class="typehead">Elimination:</span> 24% excreted in urine, 510% excreted in bile. <span class="typehead">Half-Life:</span> 62 h after single dose, 20 h after multiple doses. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab test: Monitor routine blood chemistries.</li>
<li>Monitor weight and report development of edema and/or shortness of breath.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Contact physician immediately for any of the following: Abdominal or stomach pain, persistent or severe nausea, vomiting or
            diarrhea; decreased urination; pelvic pain; moderate to severe bloating, rapid weight gain; shortness of breath; swelling
            of lower legs.
         </li>
<li>Understand that hot flashes are a common side effect of this drug.</li>
<li>Do not breast feed while using this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>